Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

2 Aug 2022

Abstract excerpt

Tisagenlecleucel (tisa-cel) is a CD19 chimeric antigen receptor (CAR) T-cell therapy that has shown exceptional efficacy in young individuals with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), leading to an overall remission rate of more than 80%. 1 Among complications of CAR T-cell therapy, macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH) is a life-threatening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35917457
DOI: 10.1182/bloodadvances.2022008256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisPMID 35917457Read ↗

Hemophagocytic Lymphohistiocytosis Secondary to Macrophage Activation Syndrome in Adult-Onset Still’s Disease: A Diagnostic and Therapeutic ChallengeSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

T cell-Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis (HLH) occurs in Non-Asians and is associated with a T cell activation state that is comparable to primary HLHSemantic proximity Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathologySemantic proximity Read ↗

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations.Semantic proximity Read ↗

Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy.Semantic proximity Read ↗

Hemophagocytic LymphohistiocytosisSemantic proximity Read ↗

Management of Refractory Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Pediatric Patients: A Case Series of Novel Therapeutics and Treatment ChallengesSemantic proximity Read ↗

Comprehensive evaluation of immune dysregulation and altered cytotoxic markers in secondary hemophagocytic lymphohistiocytosis (sHLH)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.